Clinical Trial Update: Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial update reports completed results for combining topotecan with the ATR inhibitor berzosertib (VX-970/M6620) in small cell cancers and extrapulm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Extrapulmonary Small Cell Carcinoma
• Neuroendocrine Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Topotecan (topotecan)
• VX-970 (M6620) (M6620)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-04-12